Analysts Offer Insights on Healthcare Companies: Fortress Biotech (FBIO) and Phreesia (PHR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fortress Biotech (FBIO – Research Report) and Phreesia (PHR – Research Report) with bullish sentiments.

Fortress Biotech (FBIO)

Fortress Biotech received a Buy rating and a $10.00 price target from Roth MKM analyst Jason Wittes today. The company’s shares closed last Thursday at $1.68, close to its 52-week low of $1.24.

According to TipRanks.com, Wittes is a 4-star analyst with an average return of 6.1% and a 51.3% success rate. Wittes covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Chemomab Therapeutics, and Stereotaxis.

Currently, the analyst consensus on Fortress Biotech is a Moderate Buy with an average price target of $10.00.

See the top stocks recommended by analysts >>

Phreesia (PHR)

In a report released yesterday, Stephanie Davis from Barclays maintained a Buy rating on Phreesia, with a price target of $29.00. The company’s shares closed last Thursday at $22.67.

According to TipRanks.com, Davis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.4% and a 41.6% success rate. Davis covers the Healthcare sector, focusing on stocks such as Walgreens Boots Alliance, Lifestance Health Group, and Quest Diagnostics.

Currently, the analyst consensus on Phreesia is a Strong Buy with an average price target of $29.00, a 25.8% upside from current levels. In a report issued on March 13, KeyBanc also maintained a Buy rating on the stock with a $30.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on FBIO:

• Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
• Fortress Biotech to Participate in 36th Annual ROTH Conference
• Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
• Fortress Biotech, Cyprium Therapeutics announces $4.1M grant from NINDS
• Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease